Hanmi Pharm (KRX: 128940) Hits 30% Daily Limit on $2.3B Obesity Drug Licensing Deal with Genentech
Key Points
Hanmi Pharm stock jumped 30% on August 24, 2026.
Genentech signed a potential $2.3B deal for HM17321.
Hanmi will receive $190M upfront plus milestones and royalties.
Phase 1 results and Phase 2 progress are the next key catalysts.
Hanmi Pharm shares surged 30% on August 24, 2026, hitting the daily price limit after the South Korean drugmaker announced a licensing deal with Genentech worth up to $2.3 billion. The agreement covers HM17321, an experimental obesity treatment designed to reduce body fat while preserving muscle mass. Hanmi will receive $190 million upfront, while Genentech will take over development from Phase 2. The deal has put Hanmi’s obesity pipeline in focus among investors.
Hanmi Pharm Stock Surges 30%: What Triggered the Rally?
The Hanmi Pharm Hits Daily Price Limit on August 24
Hanmi Pharm (KRX: 128940) closed at ₩540,000 on August 24, 2026, up 29.96%, after the company announced an exclusive licensing agreement with Genentech for its obesity drug candidate HM17321. The stock opened at ₩438,000 and climbed to ₩540,000, compared with ₩415,500 on August 21. Trading volume also rose above 500,000 shares, pointing to a sharp increase in investor interest.
The move came after news of a potential $2.3 billion deal. Genentech will hold rights outside South Korea, while Hanmi will retain rights in its home market.
Why the $2.3 Billion Deal Matters?
The headline value covers development, regulatory and commercial milestones. It does not mean Hanmi will receive $2.3 billion immediately. The company will get $190 million upfront, followed by potential milestone payments and tiered royalties based on future sales.
Genentech-Hanmi Pharm Deal: Key Terms Investors Need to Know
Genentech Gets Global Rights Outside South Korea
Under the agreement, Genentech receives exclusive rights to research, develop, manufacture and commercialize HM17321 worldwide, excluding South Korea. Hanmi will retain commercial rights in the South Korean market.
The deal also shifts responsibility for later-stage development. Hanmi will complete the Phase 1 trial currently underway. Genentech is expected to take over from Phase 2, giving the program access to the development resources and global capabilities of Roche’s Genentech unit.
$190 Million Upfront Plus Milestones and Royalties
Hanmi will receive $190 million upfront. The total deal value could reach about $2.3 billion, depending on development, regulatory and commercial milestones. Hanmi will also receive tiered royalties based on future product sales.
For investors, the structure is worth noting. The upfront payment provides near-term cash, but most of the announced value depends on successful clinical development, regulatory approval and eventual commercial sales.
HM17321 Explained: Why Muscle Preservation Is the Key Differentiator
A Non-Incretin Approach to Obesity Treatment
HM17321 is a long-acting urocortin-2 (UCN2) analogue being developed as a non-incretin obesity treatment. Hanmi is studying the candidate for obesity and related metabolic conditions, including type 2 diabetes and cardiovascular disease.
The drug takes a different approach from widely used GLP-1-based treatments. Hanmi says HM17321 is designed to reduce body fat while preserving or increasing muscle mass and function. That could address one concern linked to weight-loss treatment, where a reduction in overall weight does not always lead to an ideal change in body composition.
Hanmi’s preclinical studies showed weight-loss activity when HM17321 was used alone and when it was combined with GLP-1-based therapies. These findings come from preclinical research and do not establish how the treatment will perform in humans.
Weight Loss Plus Lean-Mass Preservation
Muscle preservation is a central part of the HM17321 program. Genentech described the treatment as a differentiated approach aimed at reducing fat mass while improving muscle mass and function.
That could give HM17321 a distinct position in obesity treatment if later-stage clinical trials support the findings seen in earlier research.
HM17321 Clinical Timeline: What Comes Next?
Phase 1 Trial Is Already Underway
Hanmi received U.S. FDA investigational new drug clearance in November 2025 to begin clinical testing of HM17321. The Phase 1 study is now underway, and Hanmi will complete this stage under the licensing agreement.
Genentech to Lead From Phase 2
Once Phase 1 is complete, Genentech is expected to lead development from Phase 2. Investors will be watching for Phase 1 results, safety data, dose selection and the move into larger clinical studies. Regulatory milestones will also matter.
HM17321 remains an investigational drug. The announced $2.3 billion value depends on future clinical and commercial milestones.
What the Genentech Deal Means for Hanmi Pharm Stock?
Hanmi Pharm stock now has a stronger pipeline-driven story. Before the announcement, shares had already climbed from ₩333,500 on July 31 to ₩415,500 on August 21. The August 24 rally then lifted the stock to ₩540,000.
Momentum is strong, but the size of the move also points to higher volatility. An AI stock analysis tool can help investors monitor price momentum, support levels and changes in market signals.
Hanmi Pharm Stock Forecast and Technical Analysis
The short-term trend is strongly bullish after the move to ₩540,000. The stock is also trading close to the upper end of its reported 52-week range of ₩286,000 to ₩647,000, making ₩647,000 an important longer-term reference level.
A sustained move above ₩540,000 could keep the recent momentum intact. If the stock pulls back, the earlier trading area around ₩415,500 becomes a level to watch. These are technical reference points, not guaranteed price targets.
Other market data offers a constructive view. StockHub currently shows an aggregated analyst consensus of ₩605,000.
Conclusion: Hanmi Pharm’s Obesity Pipeline Enters a Bigger League
Hanmi Pharm’s August 24, 2026 rally followed the market’s response to its Genentech licensing deal for HM17321. The potential $2.3 billion value, $190 million upfront payment and global development partnership give the obesity program greater financial backing. Clinical data will determine how the drug progresses from here. For investors, Phase 1 results and the planned Phase 2 transition are the next developments to watch.
Disclaimer:
The content shared by Meyka AI PTY LTD is for research and informational purposes only. Meyka is not a financial advisory service, and the information provided should not be treated as investment or trading advice.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)